Market Cap 29.36M
Revenue (ttm) 0.00
Net Income (ttm) -134.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.09
Volume 337,500
Avg Vol 868,858
Day's Range N/A - N/A
Shares Out 53.38M
Stochastic %K 77%
Beta 1.20
Analysts Strong Sell
Price Target $4.80

Latest News on ALXO

ALX Oncology to Host Virtual R&D Day on March 5, 2025

Feb 18, 2025, 8:00 AM EST - 2 months ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025


ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Aug 6, 2024, 4:01 PM EDT - 9 months ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors


ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 27, 2024, 4:13 AM EDT - 10 months ago

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation


ALX Oncology shares jump 9% after Jefferies upgrade

Dec 8, 2023, 8:30 AM EST - 1 year ago

ALX Oncology shares jump 9% after Jefferies upgrade


ALX Oncology Announces Pricing of Public Offering

Oct 5, 2023, 8:00 AM EDT - 1 year ago

ALX Oncology Announces Pricing of Public Offering


ALX Oncology Announces Proposed Public Offering

Oct 4, 2023, 4:10 PM EDT - 1 year ago

ALX Oncology Announces Proposed Public Offering


ALX Oncology Realigns Executive Leadership Team

Sep 6, 2023, 8:00 AM EDT - 1 year ago

ALX Oncology Realigns Executive Leadership Team


ALX Oncology Appoints Scott Garland to its Board of Directors

Nov 29, 2022, 7:00 AM EST - 2 years ago

ALX Oncology Appoints Scott Garland to its Board of Directors